12:23 PM EDT, 05/14/2024 (MT Newswires) -- (Updates with Takeda comment in penultimate paragraph.)

Scilex Holding ( SCLX ) said Tuesday the US District Court for the District of Delaware approved the settlement between the company, its subsidiary Scilex Pharmaceuticals, and Takeda Pharmaceuticals, resolving a patent infringement lawsuit related to potential gout treatment Gloperba.

The company said the US Federal Trade Commission and US Department of Justice's 45-day review period for the settlement ended.

Takeda filed a patent infringement lawsuit against Scilex ( SCLX ) in November 2023 after Scilex ( SCLX ) filed a supplemental new drug application with the US Food and Drug Administration to expand the label for Gloperba, its liquid colchicine product.

Scilex Holding ( SCLX ) said Tuesday the agreement also grants Scilex ( SCLX ) and its affiliates a non-exclusive license to certain Takeda patents under undisclosed terms.

Scilex Pharmaceutical submitted a copy of the consent judgment to the US Food and Drug Administration, aiming to convert tentative approval for Gloperba's label expansion into final approval, Scilex ( SCLX ) said.

Takeda confirmed to MT Newswires the matter was closed, saying it couldn't give additional information because the terms of the settlement are confidential.

Shares of Scilex Holding ( SCLX ) fell 1%, and Takeda rose 2.6%.

Price: 0.80, Change: -0.01, Percent Change: -0.98